Moderate To Severe Ulcerative Colitis Therapeutics
1. Velsipity patent expiration
Treatment: A method for treating ulcerative colitis by administering estrasimod l-arginine in an amount equivalent to about 2.0 mg of estrasimod; A method for treating ulcerative colitis by administering a thera...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11091435 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders |
Jun, 2036
(10 years from now) | |
| US10301262 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
Jun, 2036
(10 years from now) | |
| US8580841 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Mar, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12377071 | PFIZER | NA |
Jan, 2036
(9 years from now) | |
| US11884626 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
Jun, 2036
(10 years from now) | |
| US11007175 | PFIZER | Methods of treating conditions related to the S1P1 receptor |
Jan, 2036
(9 years from now) | |
| US10676435 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders |
Jun, 2036
(10 years from now) | |
| US9126932 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Jul, 2029
(3 years from now) | |
| US12156866 | PFIZER | Methods of treating conditions related to the S1P1 receptor |
Jan, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Dosage: TABLET
More Information on Dosage
VELSIPITY family patents
